BOSTON– OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced the appointment of Bill Steinkrauss as Chief Financial Officer. Mr. Steinkrauss brings to OcuTerra over 15 years of financial and executive leadership experience and will lead financial strategy and operations as the company continues to advance its lead asset, OTT166, for the treatment of diabetic retinopathy.
“Bill’s proven financial and business expertise coupled with his passion for helping biotech companies improve human health will be invaluable as we enter this exciting next phase of corporate growth,” said Kerrie Brady, President and CEO of OcuTerra Therapeutics. “Bill fits in seamlessly with our leadership team – as CFO, he will be an essential partner as we continue to advance our pipeline and work toward our goal to deliver a new, noninvasive treatment for diabetic retinopathy. On behalf of our Board and management team, I welcome Bill to OcuTerra.”
“I’m honored to join OcuTerra’s accomplished leadership team at such an exciting time for the company, as we advance through the Phase 2 DR:EAM clinical trial of OTT166 in diabetic retinopathy and work to prepare the company for its next phase of growth,” said Mr. Steinkrauss. “OTT166 offers the potential to address the needs of millions of patients with this retinal disease who need earlier, non-invasive therapeutic options to improve retinal health and prevent sight threatening complications. I look forward to working with the leadership team on the business strategy that will support this important work.”
Mr. Steinkrauss is the founder of OWL CFO Consulting LLC, a consulting firm providing part-time CFO services to companies in the biotechnology industry. Prior to founding OWL CFO Consulting, he served as Chief Financial Officer and Chief Administrative Officer of Curis, Inc., a publicly traded biotechnology company. In his time at Curis, he led various financings that raised over $250 million of proceeds. Mr. Steinkrauss previously worked in the finance departments at Ovascience, Inc., and at Cubist Pharmaceuticals, Inc., through its acquisition by Merck in 2015. Prior to joining the biopharma industry, Mr. Steinkrauss worked within the capital markets advisory and assurance practices at PricewaterhouseCoopers, LLP. He holds a B.S. in accounting and finance and an M.S. in accounting from Boston College. Mr. Steinkrauss is a certified public accountant.
In August, OcuTerra announced the first patient dosed in the Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy with minimal vision loss. OTT166 is a novel small molecule selective integrin inhibitor that is designed with purpose engineering to have the required physiochemical characteristics to be able to reach the retina from eye drop application.
